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Abstract 
Objective: To characterise children, adolescents and young adults infected with HIV/HCV 
vertically or before age 18 years and living in Europe regarding mode of acquisition, HCV 
genotype, clinical status and treatment.  
Design: Retrospective, cross-sectional study using pooled data from 11 European paediatric 
HIV cohorts 
Methods: Patients aged >18 months and <25 years, with HIV/HCV acquired vertically or in 
childhood, were included. Anonymised individual-patient data were collected using a 
standard protocol and modified HIV Cohorts Data Exchange Protocol.  
Results 
Of 229 patients included, 142 (62%) had vertically-acquired infection. Median age at last 
follow-up was 16.2 years. Most children had HCV genotype 1 (101/184, 55%) or 3 (57/184, 
31%). One-fifth (46/214) had a previous AIDS diagnosis (data missing on prior AIDS 
diagnoses for 15). At their last clinic visit, 70% (145/208) had no/mild immunosuppression 
(CDC stage 1) and 131 of 179 on antiretroviral therapy (ART) had undetectable HIV RNA 
(assay thresholds varied from <20 to <150 copies/ml). Overall 42% (86/204) had 
hepatomegaly in the previous year and 55% (116/213) had ALT >40 IU/L at their last test. Of 
97 patients with transient elastography, 12 had results >9 kPa; this was associated with 
duration of HCV infection (p=0.033), but not with CD4 count, ART use or gender in 
univariable analysis. Of 17 subjects with liver biopsies, 6 had bridging fibrosis and one 
cirrhosis. Twenty-five (11%) had been treated successfully for HCV. 
Conclusions 
The high proportion of patients with progressive liver disease underscores the need for close 
monitoring and earlier and more effective HCV treatment. 
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Introduction 
Worldwide around 20-30% of the 34 million HIV-infected individuals are estimated to have 
chronic HCV infection, although rates of HIV/HCV co-infection vary between and within 
populations [1]. Adult studies have demonstrated that HIV modifies the natural history of 
HCV infection, with increased probability of chronicity after infection, higher HCV viral load 
and accelerated liver disease progression amongst those chronically infected [2-4]. Chronic 
HCV infection is the main cause of liver disease and mortality in HIV-infected adults and 
also contributes to extra-hepatic morbidity and mortality, through immune activation and 
chronic inflammation [1, 5].  
Although HCV co-infection in HIV-infected adults has been much studied from 
epidemiological and clinical perspectives, with a current focus on HCV treatment with direct 
acting antivirals (DAAs)[6], much less is known about HIV/HCV co-infection in childhood 
and adolescence. The few studies on HIV/HCV co-infected children and adolescents to date 
have been small and limited to single hospitals or countries and thus important questions 
remain with respect to HCV genotype distribution, disease progression and availability and 
response to HCV treatment [7, 8]. Such changes are compounded by striking gaps in our 
understanding of the natural history of HCV infection in children without co-infection. For 
example, little is understood about the sub-group of children who progress to serious liver 
disease during childhood, or the impact of HCV-related inflammation on extra-hepatic 
manifestations. 
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Most children with HIV/HCV co-infection acquire this vertically from their mothers [9, 10] 
or through nosocomial transmission in health-care settings, although the latter route is now 
limited to specific lower- and middle-income settings where blood and medical injecting 
safety remains inadequate [11]. Adolescents may also acquire HIV/HCV co-infection 
horizontally. Young people who inject drugs may be particularly vulnerable to acquisition of 
blood-borne viruses, reflecting poor access to harm reduction services and risky injecting 
practices; increases in injecting drug use among adolescents and young people, with 
accompanying outbreaks of HIV and/or HCV have been reported in Europe [12], as well as in 
the United States [13].  
We conducted a descriptive epidemiological study of HIV/HCV co-infection in children, 
adolescents and young adults infected with HIV/HCV vertically or before age 18 within our 
European paediatric HIV cohort collaboration, in order to characterise this subpopulation 
with respect to mode of acquisition, HCV genotype, clinical status and treatment.  
Methods 
We conducted a retrospective, cross-sectional observational study, using pooled data from 
paediatric HIV cohorts in the European Pregnancy and Paediatric HIV Cohort Collaboration 
(EPPICC), which conducts epidemiological research on HIV-infected pregnant women and 
children [14] and was part of the EuroCoord network (www.eurocoord.net).  
Children aged >18 months, adolescents and young adults aged <25 years, with HIV and 
chronic HCV coinfection acquired vertically or in childhood (i.e. up to age 18 years), 
irrespective of acquisition route were eligible for inclusion. It is difficult to establish age at 
acquisition of infection in patients infected through injecting drug use. We included in our 
study population 34 young people (all living in Eastern Europe) who were reported as having 
acquired HCV via injecting drug use, but were not diagnosed until aged 18-24 years, 
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including three patients whose HIV infection was nosocomially acquired in childhood. The 
rationale for including this group of 34 young people was that the majority likely acquired 
HCV infection before age 18 years, given that initiation of injecting drug use usually starts in 
mid-adolescence in this setting [15]. Patients with positive anti-HCV antibodies who 
spontaneously cleared HCV (i.e. disappearance of HCV RNA in ≥2 consecutive serum 
samples taken 6 months apart) were excluded. Age > 18 months was chosen as inclusion 
criteria to rule out misdiagnoses due the presence of passively transferred maternal antibodies 
[16].  
Eleven cohorts from 10 countries provided anonymised individual-patient data, collected 
according to a standard protocol, with data specification based on the HIV Cohorts Data 
Exchange Protocol (www.hicdep.org). Variables included socio-demographics, data on HCV 
and HIV acquisition, disease and treatment, laboratory tests and liver investigations (e.g. 
biopsy, transient elastography (TE)). 
Definitions 
Patients were considered chronically infected if HCV RNA was detected in ≥2 blood samples 
at least 6 months apart; we included chronically infected patients who subsequently achieved 
sustained virologic response (SVR) following treatment. HIV-1 infection was defined based 
on detection of HIV-1 antibody and/or positive HIV RNA or DNA PCR in ≥2 blood samples.  
For patients with vertically-acquired HCV, birthdate was used as presumed date of HCV 
infection. For the remainder, HCV diagnosis date was used as proxy date of infection, with 
calculated duration of HCV infection therefore a minimum estimate. Geographic region of 
residence was defined as Central and Eastern Europe (Poland, Romania, Russia and Ukraine), 
Northern Europe (Belgium, Germany, Switzerland and UK) and Southern Europe (Italy and 
Spain). 
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HIV-associated immunodeficiency was defined as (i) none or mild, (ii) moderate and (iii) 
severe, based on CDC 1994 classification [17]. The limit of detection of HIV RNA assays 
ranged from <20 to <150 copies/ml. The upper limit of normal (ULN) cut-off for AST and 
ALT was defined as 40 IU/L. Division of AIDS (DAIDS) classification for grading the 
severity of adverse events was used to classify ALT and AST elevations [18].  
Liver fibrosis stages evaluated by liver biopsy scoring systems other than METAVIR were 
re-assigned METAVIR fibrosis stage [19]. Two surrogate biomarkers for liver fibrosis were 
used: AST to platelet ratio index (APRI) and the FIB-4 score, which have been validated in 
HIV/HCV co-infected adults[20, 21], but not children. APRI was calculated using the 
formula APRI=(AST/upper limit of normal) / platelets [10
9
/L] X 100 [22]. An APRI score of 
>1.5 was taken as a predictor of significant fibrosis [21-23]. The FIB-4 score was calculated 
using the formula FIB-4 =(age [years] X AST [U/L]) / (platelets [10
9
/L] X (ALT 
[U/L])1/2)[20]. A FIB-4 score of >3.25 was taken as indicator of advanced fibrosis [20].   
Medians are presented with interquartile range (IQR) and were compared using the 
Wilcoxon-Mann-Whitney test. Univariable comparisons were assessed using the Χ2 test for 
trend. Comparisons of clinical status and laboratory markers were conducted using data from 
the most recent visit date or the last available measurement, with the exception of those 
patients who achieved a SVR following HCV treatment, for whom the last measure prior to 
treatment was used. Statistics were conducted using SAS version 9.3 (SAS Institute Inc, 
Cary, NC, USA). 
Results  
A total of 229 HCV/HIV co-infected children and young people were included of whom 98 
were male and 130 female (one missing sex). Median age at last clinical follow-up was 16.2 
years (IQR, 10.0, 20.2); this was higher in Northern and Southern Europe than in Central and 
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Eastern Europe (18.1 versus 13.8 years, p<0.001). Overall, 206 participants were white, four 
were black-African, two were Asian and the rest (17, 7%) had missing ethnicity. Socio-
demographic and key clinical characteristics are presented in Table 1, stratified by mode of 
acquisition. A total of 145 (63%) had acquired HCV vertically, 15 (7%) nosocomially, 40 
(17%) through injecting drug use and 29 (13%) had unknown mode of acquisition. Mode of 
HIV acquisition was usually consistent with that for HCV infection, although three Romanian 
patients nosocomially-infected with HIV in childhood acquired HCV through injecting drug 
use (HCV diagnosed at ages 17, 19 and 23). There were 34 patients who were diagnosed with 
HCV at ≥18 years (median, age 21) overall.   
One-fifth (46/214, 21%) of patients had a history of AIDS (15 missing data), with median age 
at AIDS diagnosis of 5.1 years (IQR 1.5, 10.1); HIV encephalopathy was the most common 
AIDS-defining condition (n=11), followed by Pneumocystis jirovecii pneumonia (n=8) and 
Mycobacterium tuberculosis (n=7 pulmonary, n=3 extra-pulmonary). Overall, 5% (10/213) 
had severe immunosuppression at their most recent clinical visit (Table 1), with 70% 
(145/213) having no or mild immunosuppression. Most (179/218) patients were on 
antiretroviral therapy (ART). Among 179 on ART, 131 (73%) had undetectable HIV RNA at 
their most recent visit.  
Overall, HCV genotype (GT) was known for 184 (80%) subjects, with GT1 and GT3 
predominating and comprising overall 44% and 25% respectively (Table 1). Fifty-eight 
percent (65/113) of subjects living in Central and Eastern Europe and 55% (34/62) in 
Southern Europe had GT1 infection, compared with 22% (2/9) in Northern Europe, where the 
largest proportion of subjects had GT4 (4/9). Figure 1 presents duration of HCV infection, by 
mode of acquisition; median duration was 13.3 years (IQR 8.6, 18.1) among those vertically 
infected, although regional differences were apparent, with a median duration of 9.3 years 
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(IQR 5.7, 10.8) in Central and Eastern Europe, 18.0 years (IQR 17.9, 18.1) in Northern 
Europe and 18.2 years (IQR 16.1, 20.1) in Southern Europe (p<0.001). 
Among 204 subjects with data on presence of hepatomegaly and/or splenomegaly during the 
previous 12 months of follow-up, 86 (42%) had isolated hepatomegaly, 39 (19%) isolated 
splenomegaly and 35 (17%) had hepatosplenomegaly. A smaller proportion of vertically-
infected patients had hepatomegaly compared with those with other acquisition modes 
(36.7% [51/139] versus 56.4% [35/62], p<0.01), but the proportion with splenomegaly did 
not vary between these groups (18.8% [26/138] versus 20.6% [13/63], p=0.77).   
ALT measurements were available for 213 patients and AST for 111 patients, of whom 116 
(55%) and 68 (61%) respectively had levels above the ULN at their most recent test. A 
significantly greater proportion of patients with non-vertically acquired HCV had elevated 
liver enzymes compared with vertically-infected individuals (Table 2).  APRI and FIB-4 
scores are summarized in Table 2. A total of 97 children and young people had TE results 
available (Table 2), with median age at investigation of 17.6 years (IQR, 13.0, 21.6 years). Of 
the 12 patients with TE results >9.5 kPa, eight had GT1 (67%) and two each had GT3 and 
GT4. Duration of HCV infection among those with TE results of <9.5 kPa was significantly 
lower (10.7 years, IQR 3.7, 18.0) compared with subjects with greater liver stiffness (18 
years, IQR 13.9, 19.2) (p=0.033). There was no association between TE results and CD4 
count categories, ART use or gender in univariable analysis. 
Seventeen (8%) subjects from eight cohorts had results from at least one liver biopsy 
reported. Twelve (71%) of these patients had acquired HCV vertically, one via IDU and three 
nosocomially (one unknown). Median age at first biopsy was 13 years (range, 3-22). There 
was no association between TE results and having a biopsy (p=0.22) or with having an 
elevated ALT or AST (p=0.6). Seven patients had a fibrosis score of F3 and one of F2, with 
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the remainder having no fibrosis or portal fibrosis without septa; moderate inflammation was 
present in 13 biopsies and mild inflammation in three. Two patients had repeat liver biopsies: 
one child, aged 9 and 11.5 years at first and second biopsies, had improvement of both 
fibrosis and inflammation by one score with no HCV treatment given. The second young 
person (vertically-infected, GT3a), aged 14 and 19.5 at first and second biopsies, progressed 
from periportal and portal fibrosis to cirrhosis and died of decompensated cirrhosis aged 21 
years.  
Overall, 174 (76.0%) of the 229 patients were HCV treatment-naïve, 25 (10.9%) had been 
unsuccessfully treated with pegylated interferon plus ribavirin (pegIFN/RBV), five (2.2%) 
had completed pegIFN/RBV treatment but were awaiting 24 weeks post-treatment SVR 
(SVR24) result and 25 (10.9%) had been treated successfully. Median age at initiation of 
pegIFN/RBV treatment was 17.2 years (IQR, 3.5, 24.0). HCV genotype distribution was 28 
(51%) GT1, one GT2, 21 (38%) GT3 and three (5%) GT4 (two missing).  Forty-seven (85%) 
of the patients on pegIFN/RBV were receiving concurrent ART. The SVR24 rates were 32% 
(8/25) for GT1 and 79% (15/19) for GT3; the one treated patient with GT2 achieved an 
SVR24, but none of the three treated patients with GT4 did so.  
In addition to the death above, one other vertically-infected patient died following 
Pneumocystis jirovecii pneumonia, at age 20. 
 
Discussion 
In this study we have characterized the population of children and young people living with 
vertically or childhood-acquired HIV/HCV co-infection and followed in European paediatric 
HIV cohorts. No previous description of the HIV/HCV epidemic in children and adolescents 
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across the European region exists. We demonstrate some important regional differences, 
show that chronic HCV infection in the presence of HIV co-infection, is associated with 
progressive liver disease in a  substantial proportion of these children and young people, and 
highlight the low HCV treatment rates. 
The cohort of vertically-infected patients living in Northern and Southern Europe were older 
than those living elsewhere. This reflects the general aging of paediatric HIV cohorts, 
declining HIV mother-to-child transmission (MTCT) and the decreasing HCV prevalence in 
HIV-positive women in these regions [24, 25]. In contrast, Central and Eastern Europe has a 
younger HIV epidemic, higher HIV MTCT rates (particularly among women who inject 
drugs, reflecting poorer access to optimum interventions) and a greater proportion of 
HIV/HCV co-infected pregnant women [26, 27]. In our study, similar to the adult genotype 
distribution in Global Burden of Disease European regions reported in a recent meta-analysis 
[26], GT1 was the most common followed by GT3, although GT4 was the most common 
genotype in Northern Europe. Our small numbers preclude firm conclusions on genotype 
distribution [28].  Among HCV mono-infected children in the Italian Observatory Study, 
GT1 and GT2 were prevalent among adolescents, but infections with GT3 and GT4 were 
increasing [29].   
It is expected that most children becoming HCV-infected in Europe will develop chronic 
infection, with around 7-20% experiencing spontaneous viral clearance [29, 30].  The limited 
literature available on HIV/HCV co-infected children suggests they may be less likely to 
spontaneously clear HCV than adults or than mono-infected children [7]. Among children 
with chronic HCV mono-infection, 2-3% are expected to progress to cirrhosis in childhood 
[29]. As probability of liver fibrosis generally increases with age and duration of infection, 
young adults with HCV acquired vertically or in early childhood may be at risk of end-stage 
liver disease in early adulthood [31, 32]. However, understanding of liver fibrosis progression 
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in childhood and beyond in individuals with vertically or childhood-acquired HCV is 
incomplete. Mohan et al found that 30% of HCV mono-infected children had more severe 
fibrosis in a repeat biopsy conducted on average 6 years after their first [33], demonstrating 
that liver fibrosis does progress in childhood; other studies show that some children can 
progress rapidly, developing severe fibrosis after relatively short durations of HCV infection 
[34, 35].  
Questions regarding rates of and risk factors for hepatic fibrosis progression in HIV/HCV co-
infected adults also remain [36, 37]. In one study among nearly 300 HIV/HCV co-infected 
adults with repeat liver biopsies, 34% had progression of ≥1 METAVIR stage over a median 
2.5 years despite 86% having no or minimal fibrosis at their first biopsy; risk factors for 
progression included elevated liver enzymes, obesity and hepatic steatosis, but not ART, CD4 
count or HIV RNA levels [36]. In the present study, of the 17 patients with liver biopsies, 
40% had bridging fibrosis and one went on to develop cirrhosis. However, these biopsy 
results should be interpreted cautiously, due to small numbers and potential bias. We were 
able to calculate APRI and FIB-4 scores for around half of our study population and TE 
results were available for 42% of our study population but the value of these scores and of TE 
has not yet been established in children.  
More than half of our participants had raised ALT/AST at their most recent visit, higher than 
the 30% reported for HCV mono-infection in the European Paediatric Hepatitis C Network 
(EPHN) [30]. A Spanish study also reported higher ALT levels in HIV-co-infected versus 
mono-infected children [7]. Around 40% of our study population had hepatomegaly and/or 
splenomegaly during the previous year, compared with 10% reported in the EPHN [30]; this 
may be partly explained by the larger numbers of participants with non-vertically acquired 
infection in our study, who were more likely to have hepatomegaly than vertically-infected 
children and young people.  
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Historical cohorts of HCV mono-infected children present a clinical picture of a generally 
mild disease in terms of symptoms, laboratory and histopathology findings [29, 30]. Our 
findings suggest worse liver disease in HIV/HCV co-infected children and young people than 
in those with HCV mono-infection [29, 32], consistent with adult studies [1, 5, 36]. Chronic 
HCV infection in the context of HIV co-infection may thus be considered as a potentially 
aggressive infection associated with severe and rapidly progressing liver damage. We found 
that liver enzyme elevations at the most recent clinic visit were significantly more common 
among non-vertically infected patients. This group also had greater probability of significant 
fibrosis according to APRI score, despite shorter duration of HCV infection. Future research 
using longitudinal data, accounting for other factors associated with development of liver 
fibrosis is required. 
Regarding HIV disease, most patients had previously experienced moderate or severe clinical 
symptoms, but most had no or mild immunosuppression at their most recent visit. The finding 
that three-quarters of those treated had undetectable HIV RNA load is similar to other 
paediatric HIV cohorts [14, 38]. It is debatable whether HCV progression is modified where 
HIV infection is well-controlled; adult studies have shown increased risk of non-liver related 
morbidity and mortality in HCV co-infected individuals due to persistent inflammation and 
immune activation [1, 5], providing the rationale to treat HCV in this population as early as 
possible.  
Current standard of care for paediatric HCV treatment remains pegIFN/RBV as DAAs have 
not yet been licensed for paediatric use [39]. Current guidelines recommend that treatment 
with pegIFN/RBV is considered for children with persistently elevated liver enzymes and/or 
liver fibrosis [34]. Adult trials show that HIV/HCV co-infected individuals do as well, or 
even better in achieving SVR after DAA treatment than HCV-mono-infected persons[6, 40]. 
Our findings, together with a previous small case series [8], demonstrate worse outcomes 
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with pegIFN/RBV in children and young people with HIV/HCV co-infection versus HCV 
mono-infection, particularly for GT1 and GT4 [41, 42]. In a separate analysis, we showed 
that HCV treatment coverage in this population varied substantially by country, with the 
highest treatment rates in Russia (61%), whilst no children in some countries had been 
treated. Patients were significantly more likely to be treated if they had advanced fibrosis as 
defined by TE (e.g. five-fold increased odds of treatment for patients with ≥9.6 vs ≤7.2 kPa) 
and if they were aged more than 18 years [43].  
This study was limited by its cross-sectional, retrospective design and the observational data, 
which resulted in missing data for some variables and limited details regarding TE and liver 
biopsy methodology, which were carried out and interpreted as per routine practice at the 
participating cohorts’ sites. Interpretation of the liver biopsy results must take into account 
the fact that the 17 patients with biopsies were from eight cohorts and biopsies were assessed 
by different pathologists using different grading and staging systems.  Duration of HCV 
infection will have been underestimated in patients with non-vertical mode of transmission as 
diagnosis date was taken as a proxy. Interpretation of the APRI, FIB-4 and TE results should 
allow for the absence of large paediatric HCV studies validating these markers.  
This is the first study describing a large population of HIV/HCV co-infected children and 
young people across Europe. As clinical management of co-infected children has previously 
relied on extrapolation from adult studies, our findings will contribute to better understanding 
of this co-infection in childhood. We describe a substantial proportion of HIV/HCV co-
infected children and young people with progressive liver disease, with low response to 
standard treatment with pegIFN/RBV among the minority treated to date. Considering this, 
the improved life expectancy in HIV-infected children and the excellent outcomes in adults 
with HIV/HCV infection treated with DAAs, these observations support the need of 
HIV/HCV co-infected children for HCV treatment.  
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Table 1: Socio-demographic and clinical characteristics, by mode of HCV acquisition 
 Vertical 
acquisition 
Other acquisition  
    N (%)  
N 145 84  
Country of residence 
  Belgium 
  Germany 
  Italy 
  Poland 
  Romania 
  Russia 
  Spain 
  Switzerland 
  UK 
  Ukraine 
 
2 (1.4) 
1 (0.7) 
19 (13.1) 
3 (2.1) 
0 
18 (12.4) 
44 (30.3) 
3 (2.1) 
2 (1.4) 
53 (36.6) 
 
1 (1.2) 
0 
1 (1.2) 
1 (1.2) 
33 (39.3) 
31 (36.9) 
2 (2.4) 
0 
1 (1.12) 
14 (16.7) 
 
Region of origin 
  CE Europe 
  N Europe 
  S Europe   
  Africa 
  Missing/unknown 
 
74 (51.0) 
3 (2.1) 
52 (35.9) 
2 (1.4) 
14 (9.7) 
 
79 (94.0) 
0 
3 (3.6) 
2 (2.4) 
0 
 
 
 
 
 
p<0.001 
Current HIV clinical stage 
  Not symptomatic 
 
5 (3.4) 
 
0 
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  CDC A / WHO 1 or 2 
  CDC B / WHO 3 
  CDC C / WHO 4 
  unknown 
47 (32.4) 
52 (35.9) 
24 (16.6) 
17 (11.7) 
29 (34.5) 
27 (32.1) 
17 (20.2) 
11 (13.1) 
 
 
 
p=0.45 
Current CDC immune 
stage 
(i) none or mild suppression 
(ii) moderate suppression 
(iii) severe suppression 
unknown 
 
101 (69.7) 
24 (16.6) 
6 (4.1) 
14 (9.7) 
 
44 (52.4) 
29 (34.5) 
4 (4.8) 
7 (8.3) 
 
 
 
 
p=0.018 
Age at last follow-up 
  <11 years 
  11-17 years 
  18-24 years 
 
60 (41.4) 
42 (29.0) 
43 (29.7) 
 
7 (8.3) 
24 (28.6) 
53 (63.1) 
 
 
 
p<0.001 
Age at HCV diagnosis 
  Median (IQR), years 
 
2.3 (1.5, 6.0) 
 
17.3 (10.0, 21.5) 
 
p<0.001 
HCV genotype 
  1 
  2 
  3 
  4 
unknown 
 
66 (45.5) 
4 (2.8) 
40 (27.6) 
17 (11.7) 
18 (12.4) 
 
35 (41.7) 
1 (1.2) 
17 (20.2) 
4 (4.8) 
27 (32.1) 
 
 
p=0.50 
(among 
known 
values) 
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Table 2: Liver enzyme measures, non-invasive markers of fibrosis and transient 
elastography 
 Vertically 
acquired 
HCV 
HCV 
acquired 
by other 
routes 
  
Total 
  N (%) 
ALT     
Number with measurement available* 131 82  213 
DAIDS grading 
 non-elevated 
 mild elevation (grade 1) 
 moderate elevation (grade 2) 
 severe elevation (grade 3) 
 
83 (63.4) 
37 (28.2) 
11 (8.4) 
0 
 
33 (40.2) 
29 (35.4) 
13 (15.9) 
7 (8.5) 
 
 
 
 
p=0.0007
# 
 
116 (54.5) 
66 (31.0) 
24 (11.3) 
7 (3.3) 
AST     
Number with measurement available* 77 34  111 
DAIDS grading 
 non-elevated 
 mild elevation (grade 1) 
 moderate elevation (grade 2) 
 severe elevation (grade 3) 
 
47 (61.0) 
27 (35.1) 
2 (2.6) 
1 (1.3) 
 
15 (44.1) 
8 (23.5) 
7 (20.6) 
4 (11.8) 
 
 
 
 
p=0.0002
#
 
 
62 (55.9) 
35 (31.5) 
9 (8.1) 
5 (4.5) 
APRI     
Number with biomarker available 79 48  127 
APRI score     
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 
 
  <0.5 (no significant fibrosis) 
 0.5 – 1.5   
 >1.5 (significant fibrosis)  
 
45 (57.0) 
29 (36.7) 
5  (6.3) 
 
12 (25.0) 
23 (47.9) 
13 (27.1) 
 
 
p=0.0002 
57 (44.9) 
52 (40.9) 
18 (14.2) 
FIB-4     
Number with biomarker available 79 48  127 
FIB-4 groups 
     ≤1.45     (no advanced fibrosis) 
     1.46 – 3.25 
     >3.25     (advanced fibrosis / 
cirrhosis) 
 
73 (92.4) 
5  (6.3) 
1  (1.3) 
 
41 (85.4) 
6 (12.5) 
1  (2.1) 
 
 
 
 
 
114 (89.8) 
11  (8.7) 
2   (1.6) 
 
Transient elastography     
Number with measurement available 62 35  97 
Liver stiffness (kPa)  
  <5.8 
 5.9-9.5 
 9.6-12.5 
 >12.5 
 
30 (48.4) 
23 (37.1) 
6 (9.7) 
3 (4.8) 
 
11 (31.4) 
21 (60.0) 
2 (5.7) 
1 (2.9) 
 
 
 
 
p=0.09
^ 
 
41 (42.3) 
44 (45.4) 
8 (8.2) 
4 (4.1) 
* at last clinic visit; 
#
 Χ2 test with grades 2 and 3 grouped together;^ Χ2 test with 9.6-12.5 and 
>12.5 grouped together 
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Figure 1: Duration of HCV infection, by mode of acquisition 
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